This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Novel Therapies for Malignant Melanoma: Immune Checkpoint Inhibitors, Targeted BRAF Inhibitors and Oncolytic Viral Therapy Approaches

Novel Therapies for Malignant Melanoma: Immune Checkpoint Inhibitors, Targeted BRAF Inhibitors and Oncolytic Viral Therapy Approaches

Format

Webcast

Time to Complete

1.50 hours

Released

July 7, 2016

Expires

July 7, 2017
Add to Queue


Maximum Credits

1.50 / AMA PRA Category 1 Credit(s)TM

Accredited Provider

Jointly provided by A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet

Commercial Supporter

Supported by Amgen, Inc.

Program Description

This webcast is intended to improve care of patients with melanoma by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Intended Audience

This webcast is designed to meet the educational needs of hematologists/oncologists, surgical oncologists, radiation oncologist, dermatologists and other health care professionals who diagnose, treat, and manage patients with melanoma.

Educational Objectives

As a result of participating in the activity, learners should be better able to:

  • Outline the role of T-VEC oncolytic viral therapy alone and/or in combination with other immunotherapeutic agents for malignant melanoma
  • Identify and select novel therapeutic agents targeting BRAF mutant malignant melanomas
  • Evaluate PD-1/PD-L1 interactions that contribute to better outcomes for patients with malignant melanoma

Conflict Of Interest Disclosure Policy

It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.

Faculty

Keith Flaherty, MD
Director, Henri & Belinda Termeer Center for Targeted Therapy
Richard Saltonstall Chair in Oncology
Massachusetts General Hospital Cancer Center
Boston, MA

Dr. Flaherty discloses:
Consultant: Ariad, Lilly USA, LLC, Novartis, and Roche

Ryan J. Sullivan, MD
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, MA

Dr. Sullivan discloses:
Advisory Board/Consultant: Novartis, Prometheus
Research Sponsorship: Adaptive Biotechnologies, Bristol Myers Squibb, Merck, and Prometheus

Planners' and Managers' Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Keith Flaherty, MD, discloses that he is a consultant for Ariad, Lilly USA, LLC, Novartis, and Roche.

Kamatham A. Naidu, PhD (CancerNet), has no relevant financial relationships to disclose.

Credit

1.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet. The A. Webb Roberts Center for CME of Baylor Health Care System is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

NON-ENDORSEMENT OF PRODUCTS
The A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas do not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.

Instructions

There are no fees for participating and receiving CME credit for this webcast. During the period July 7, 2016 through July 7, 2017, participants must read all of the material and study the educational webcast.

This webcast includes text, graphics, and may include multimedia features.

To obtain credit, a score of 80% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the CME Provider at 214-820-2317.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

A. Webb Roberts Center for CME of Baylor Health Care System observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support. To contact CME Provider, call 214-820-2317.

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue